<DOC>
	<DOCNO>NCT01918241</DOCNO>
	<brief_summary>This study ass Efficacy Safety different dos PEG-rhG-CSF single-dose G-CSF Preventing Chemotherapy-induced Neutropenia .</brief_summary>
	<brief_title>Saftey Efficacy Pegfilgrastim Preventing Chrmotherapy-induced Neutropenia</brief_title>
	<detailed_description>The study consist screening period 21-day chemotherapy period chemotherapy treatment cycle ( ) .Screening subject accord inclusion criterion exclusion criterion 2 week chemotherapy , screen successfully patient eligible study . The 1st chemotherapy treatment cycle define subject screen period , subject treat TC EC regimen 1st day , aim screen Chemotherapy-induced Neutropenia ≥grade 3 ( ANC＜1.0×10^9/L ) eligible enter 2nd chemotherapy treatment cycle , otherwise quit study . On 1st day cycle 2 , subject treat regimen 1st chemotherapy treatment cycle , receive test drug control 3rd day observe efficacy safety . 【Primary Outcome Measures】 : • Duration ≥grade 3 neutropenia cycle 2 【Secondary Outcome Measures】 : - Incidence ≥grade 3 neutropenia induce ; - Incidence febrile neutropenia ; - Duration ANC chemotherapy finish ANC nadir minimum ANC ; - Duration ANC recovery nadir 2.0×10^9/L .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Age:1870 years； Comfirmed advance tumor patient histopathological regard initialtreatment adjuvant , neoadjuvant chemotherapy , suitable chemotherapy canboplatin combine taxol cyclophosphamide combine pharmorubicin opinion investigator； Performance status（EOCG）≤1； Normal human peripheral blood eligible chemotherapy , WBC≥3,500 per cubic millilit , ANC ≥ 1,500 per cubic milliliter , PLT ≥ 100,000 per cubic milliliter； Normal ECG examination； Without liver metastasis patient : level ALT、TBIL、AST 2.5 time upper normal limit ; Liver metastasis patient : level ALT、TBIL、AST 5 time upper normal limit ; Renal function indices：the level Cr、BUN bothe 1.25 time upper normal limit ; Life expectancy ＞3 month ; Signed informed consent . Be treat radiotherapy nearly 4 week ( included local radiotherapy bone metastasis ) ; Be treat hemopoietic stem cell transplantation bone marrow transplant； Not adequately control infection ( e.g . ANC ≥ 12,000 per cubic milliliter , temperature &gt; 38.2℃ ) Evidence metastatic disease bone marrow , malignant tumor （not include cured basal cell carcinoma endometrial carcinoma）； Subjects unconscious symptomatic brain metastases； Subjects serious heart、liver renal disease ; Subjects serious diabetes poor control glycemia ; Pregnant breastfeed period female ; Be treat antibiotic 72 hour currently treat antibiotic ; Treated PEGrhGCSF past ; Participated 3 3 clinical trial nearly year ( subject ) clinical trial nearly 3 month ; Allergic disorder allergy subject know hypersensitivity filgrastim product administer dosing ; Suspected comfirmed evidence drug、treatment drug alcohol abuse ; Serious Neurological disorder would affect consent observation ; Other condition opinion investigator preclude enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Pegylation</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Satety</keyword>
</DOC>